8-K: Werewolf Therapeutics Faces Nasdaq Delisting Threat Due to Low Share Price

Werewolf Therapeutics received a notice from Nasdaq indicating that its common stock price has fallen below the minimum bid price requirement of $1.00 per share for continued listing.

Summary

• Werewolf Therapeutics received a deficiency letter from Nasdaq on May 13, 2025, because its stock price closed below $1.00 per share for 30 consecutive business days.
• This violates Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Global Select Market.
• The notice does not immediately affect the listing of the company's stock.
• Werewolf Therapeutics has an initial 180-day period, expiring on November 10, 2025, to regain compliance by maintaining a stock price of at least $1.00 for a minimum of 10 consecutive business days.
• If the company fails to regain compliance within the initial period, it may be eligible for an additional 180-day compliance period by transferring its listing to the Nasdaq Capital Market, provided it meets other listing requirements.
• If the company fails to meet the requirements during the second compliance period, Nasdaq could issue a delisting notice, which the company may appeal.
• There is no guarantee that the company will regain compliance or that an appeal would be successful.
• The company intends to monitor its stock price and evaluate options to regain compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and uncertainty surrounding the company's ability to regain compliance. While the company has options, the situation presents a significant challenge.

Positives

• The notice has no immediate effect on the listing of the company's common stock.
• The company has an opportunity to regain compliance within a specified timeframe.
• The company may be eligible for an additional compliance period by transferring to the Nasdaq Capital Market.

Negatives

• The company's stock price has been below $1.00 for 30 consecutive business days, triggering the Nasdaq deficiency notice.
• Failure to regain compliance could lead to delisting from the Nasdaq Global Select Market.
• There is no guarantee that the company will be able to regain compliance or that an appeal would be successful.

Risks

• The company faces the risk of delisting from the Nasdaq Global Select Market if it cannot regain compliance with the minimum bid price requirement.
• The company's stock price may be negatively impacted by the delisting notice.
• There is uncertainty regarding the company's ability to regain compliance within the given timeframe.

Future Outlook

The company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement; however, there can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement.

Management Comments

• The Company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement.

Industry Context

Many small-cap biotech companies face challenges in maintaining their stock price above $1.00, especially during periods of market volatility or negative clinical trial results. Delisting from major exchanges can significantly impact investor confidence and access to capital.

Comparison to Industry Standards

• Other biotech companies that have faced similar delisting notices include [hypothetical company A] and [hypothetical company B].
• These companies often explore options such as reverse stock splits, attracting new investment, or transferring to a different exchange to maintain their listing.
• The success of these strategies varies depending on the company's financial health and market conditions.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding the company's future.
• The company's ability to raise capital and fund its research and development programs may be negatively impacted.

Next Steps

• The company will monitor its stock price.
• The company will evaluate options to regain compliance with the Nasdaq minimum bid price requirement.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, Werewolf Therapeutics, stock price